While technology lately has been framed in the context of computer hardware or software, it can also apply to the broader field of medicine. Therefore, investors should consider the viable field of MedTech stocks. According to a McKinsey & Company report, over the next five years, the industry may see the fastest growth in the realms of cardiovascular health, digital healthcare and robotics. Overall, the MedTech ecosystem reached a valuation of $503.2 billion last year , per Future Market Insights. By 2033, the sector could be worth nearly $776.5 billion. If so, the expansion would imply a compound annual growth rate (CAGR) of 4.4%. Fundamentally, chronic conditions such as diabetes, cardiovascular disease and obesity are on the rise globally. Therefore, MedTech stocks will likely benefit from burgeoning relevance. While it may be tempting to view the medical innovation space cynically, we should also note that chronic disease imposes a collective economic impact. Therefore, these MedTech stocks offer a win-win for everyone.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. ` The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30 , according to Benzinga Pro . Here''s the latest list of major oversold players in this sector, having an RSI near or below 30. Edwards Lifesciences Corp (NYSE: EW ) On July 24, Edwards Lifesciences reported worse-than-expected second-quarter sales results and issued third-quarter guidance below estimates. Also, the company acquired JenaValve and Endotronix. The company''s stock fell … Full story available on Benzinga.com

Mad Money'' host Jim Cramer weighs in on stock including: Borr Drilling, Blackstone, Dexcom, Edwards Lifesciences, Lowe''s, Joby, and Marvell.

Have you assessed how the international operations of Edwards Lifesciences (NYSE: EW ) performed in the quarter ended June 2024? For this medical device maker, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects. In today''s increasingly interconnected global economy, a company''s ability to tap into international markets can be a pivotal factor in shaping its overall financial health and growth trajectory. For investors, understanding a company''s reliance on overseas markets has become increasingly crucial, as it offers insights into the company''s sustainability of earnings, ability to tap into diverse economic cycles and overall growth potential. Being present in international markets serves as a counterbalance to domestic economic challenges while offering chances to engage with more rapidly evolving economies. However, this kind of diversification introduces challenges like currency fluctuations, geopolitical uncertainties and varying market trends.

Edwards Lifesciences stock dropped by over 31% after cutting TAVR guidance. Read why I remain confident in EW stock''s long-term growth potential.

The CNN Money Fear and Greed index showed a further decline in the overall market sentiment, with the index remaining in the “Fear” zone on Thursday. U.S. stocks closed mixed on Thursday, with the S&P 500 and the Nasdaq Composite moving lower after recording sharp losses in the prior session. Shares of leading technology companies, including, Nvidia (NASDAQ: NVDA ), while Meta Platforms (NASDAQ: META ), Microsoft (NASDAQ: MSFT ) and Alphabet (NASDAQ: GOOG ) (NASDAQ: GOOGL ) settled lower on Thursday. Ford Motor Company (NYSE: F ) shares tumbled over 18% on Thursday after the company missed analyst EPS estimates for the 2024 fiscal year second quarter. Shares of Edwards Lifesciences Corporation (NYSE: EW ) dipped 31% after the company … Full story available on Benzinga.com

Edwards Lifesciences shares ($EW) plummeted about 31% in today’s trading after J.P. Morgan and Truist both downgraded the medical technology compan…

Edwards Lifesciences shares swooned after the company damped expectations for heart valve replacement sales growth on Wednesday.

https://www.investing.com/news/company-news/edward-lifesciences-hits-52week-low-trading-at-6053-93CH-3537346

Edwards Lifesciences Corp (NYSE: EW ) reported Wednesday second-quarter adjusted EPS of 70 cents, beating the consensus of 69 cents . The sales increased 7% (+8% on constant currency) to $1.632 billion, below the consensus of $1.653 billion. The company reported Transcatheter Aortic Valve Replacement (TAVR) sales of $1 billion, which grew 5%, or 6% on a constant currency basis . Edwards’ competitive position did not meaningfully change globally, although the company experienced some regional pressures, and pricing was maintained. The company also agreed to acquire JenaValve Technology , a company focused on the transcatheter treatment of aortic regurgitation (AR). Edwards anticipates FDA approval of the JenaValve Trilogy Heart Valve System in late 2025, which will represent the first approved therapy for patients suffering from AR. Building on an investment made in 2016, the company exercised its option to acquire Endotronix , a heart failure (HF) management … Full story available on Benzinga.